The therapeutic effect of interleukin-22 in high androgen-induced polycystic ovary syndrome

J Endocrinol. 2020 May;245(2):281-289. doi: 10.1530/JOE-19-0589.

Abstract

Polycystic ovary syndrome (PCOS) is a complex syndrome involving both endocrine and metabolic disorders. Gut microbiota and the intestinal immune factor IL-22 play an important role in the pathogenesis of PCOS. However, the therapeutic role of IL-22 in high androgen-induced PCOS mice is not clear. We aimed to determine the therapeutic effects of IL-22 on the DHEA-induced PCOS mouse model and to explore the possible mechanism of IL-22 in regulating hyperandrogenism-associated PCOS. Insulin resistance levels and ovarian functions were investigated in DHEA-induced PCOS mice with or without additional IL-22 treatment. We found that IL-22 could reverse insulin resistance, disturbed estrous cycle, abnormal ovary morphology, and decreased embryo number in DHEA mice. Mechanistically, IL-22 upregulated the browning of white adipose tissue in DHEA mice. This study demonstrated that IL-22-associated browning of white adipose tissue regulated insulin sensitivity and ovarian functions in PCOS, suggesting that IL-22 may be of value for the treatment of PCOS with a hyperandrogenism phenotype.

Keywords: IL-22; hyperandrogenism; insulin resistance; ovarian function; polycystic ovary syndrome.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Androgens
  • Animals
  • Disease Models, Animal
  • Estrous Cycle / drug effects
  • Female
  • Hyperandrogenism / chemically induced
  • Hyperandrogenism / complications
  • Insulin Resistance / physiology
  • Interleukin-22
  • Interleukins / pharmacology*
  • Mice
  • Ovary / physiopathology
  • Polycystic Ovary Syndrome / chemically induced
  • Polycystic Ovary Syndrome / drug therapy*
  • Polycystic Ovary Syndrome / physiopathology

Substances

  • Androgens
  • Interleukins